Biogen Idec Initiates Phase III Acute Decompensated Heart Failure Trial
Posted on: Friday, 22 August 2008, 09:01 CDT
Biogen Idec has initiated a Phase III clinical trial of intravenous Adentri, an adenosine A1 receptor antagonist, for acute decompensated heart failure patients with renal insufficiency.
The trial will evaluate Adentri, which is being developed under a licensing agreement with CV Therapeutics, or placebo in addition to standard of care in approximately 900 patients in 21 countries globally, including the US.
The Trident-1 study is a Phase III randomized, multi-center, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of intravenous Adentri dosed up to five days on body weight in acute decompensated heart failure patients with impaired renal function.
Barry Ticho, vice president of cardiopulmonary and emerging therapies at Biogen, said: "Following lixivaptan, Adentri marks the second novel compound in Biogen Idec's cardiopulmonary franchise that is in Phase III clinical trials for heart failure patients. We look forward to advancing this and our other programs in the future."
Source: Datamonitor
Related Articles
- UT Southwestern Patient Receives Newest-Generation Heart Failure Device
- Nile Therapeutics Reports Positive Interim Data From Heart Failure Study
- Palatin Technologies's Phase I Heart Failure Trial Meets Endpoint
- Home Health Monitoring Systems for Heart Failure Patients Emerge As the Healthcare Industry Moves From Intervention-Based Care to Preventive Care
- Merck's Investigational Rolofylline Associated With Improved Dyspnea and Preserved Renal Function in Acute Heart Failure Patients in a Phase III Pilot Study
- Palatin's Cardiac Drug Meets End Point in Phase I Heart Failure Trial
- Nile Initiates Phase I Heart Failure Study
- Researchers Seek to Determine Whether Genetic Variations May Affect Patients' Response to New Heart Failure Therapy; Data Presented at Heart Failure Society of America Annual Meeting
- CardioDynamics Announces New Study Results Showing ICG Identifies Patients at Risk for Heart Failure-Related Events
- Protein Design Labs Reports Positive Results in Phase II Clinical Trial (SIRIUS II) of Ularitide for Decompensated Congestive Heart Failure
 |
 |
User Comments (0)
RSS Feeds